247 related articles for article (PubMed ID: 33409878)
1. Comparison of Oocyte and Embryo Quality Between Random Start and Controlled Ovarian Stimulation Cycles in Cancer Patients Undergoing Fertility Preservation.
İsrafilova G; Şükür YE; Özkavukcu S; Sönmezer MA; Atabekoğlu CS; Özmen B; Berker B; Aytaç R; Koç A; Sönmezer M
Reprod Sci; 2021 Aug; 28(8):2200-2207. PubMed ID: 33409878
[TBL] [Abstract][Full Text] [Related]
2. Random Start Ovarian Stimulation for Oocyte or Embryo Cryopreservation in Women Desiring Fertility Preservation Prior to Gonadotoxic Cancer Therapy.
Danis RB; Pereira N; Elias RT
Curr Pharm Biotechnol; 2017 Nov; 18(8):609-613. PubMed ID: 28786354
[TBL] [Abstract][Full Text] [Related]
3. COH outcomes in breast cancer patients for fertility preservation: a comparison with the expected response by age.
Malacarne E; Devesa M; Martinez F; Rodriguez I; Coroleu B
J Assist Reprod Genet; 2020 Dec; 37(12):3069-3076. PubMed ID: 32945994
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
[TBL] [Abstract][Full Text] [Related]
5. Ovarian tissue cryopreservation can be combined simultaneously with oocyte retrieval after controlled ovarian hyperstimulation.
Puy V; Dupeux M; Mayeur A; Grynberg M; Benoit A; Bendayan M; Zhegari F; Hesters L; Gallot V; Prevot S; Frydman N; Sonigo C
Hum Reprod; 2023 May; 38(5):860-871. PubMed ID: 36860186
[TBL] [Abstract][Full Text] [Related]
6. Random-start controlled ovarian hyperstimulation with letrozole for fertility preservation in cancer patients: case series and review of literature.
Keskin U; Ercan CM; Yilmaz A; Babacan A; Korkmaz C; Duru NK; Ergun A
J Pak Med Assoc; 2014 Jul; 64(7):830-2. PubMed ID: 25255597
[TBL] [Abstract][Full Text] [Related]
7. Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers.
Goldrat O; Van Den Steen G; Gonzalez-Merino E; Dechène J; Gervy C; Delbaere A; Devreker F; De Maertelaer V; Demeestere I
Reprod Biol Endocrinol; 2019 Jan; 17(1):3. PubMed ID: 30606204
[TBL] [Abstract][Full Text] [Related]
8. Ovarian response and follow-up outcomes in women diagnosed with cancer having fertility preservation: Comparison of random start and early follicular phase stimulation - cohort study.
Muteshi C; Child T; Ohuma E; Fatum M
Eur J Obstet Gynecol Reprod Biol; 2018 Nov; 230():10-14. PubMed ID: 30227359
[TBL] [Abstract][Full Text] [Related]
9. Ovarian response to stimulation for fertility preservation in women with hematologic cancer.
Brun T; Dion L; Jaillard S; Bales D; Domin M; Lavoué V; Levêque J; Houot R; Duros S
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101925. PubMed ID: 33010467
[TBL] [Abstract][Full Text] [Related]
10. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation.
Cakmak H; Katz A; Cedars MI; Rosen MP
Fertil Steril; 2013 Dec; 100(6):1673-80. PubMed ID: 23987516
[TBL] [Abstract][Full Text] [Related]
11. Response to ovarian stimulation is not impacted by a breast cancer diagnosis.
Quinn MM; Cakmak H; Letourneau JM; Cedars MI; Rosen MP
Hum Reprod; 2017 Mar; 32(3):568-574. PubMed ID: 28122888
[TBL] [Abstract][Full Text] [Related]
12. Controlled ovarian stimulation outcomes of fertility preservation procedures in newly diagnosed breast cancer patients: a retrospective study from a single-tertiary-IVF centre.
Sahin G; Goker ENT; Gokmen E; Yeniay L; Acet F; Zekioglu O; Tavmergen E
J Obstet Gynaecol; 2022 Apr; 42(3):518-523. PubMed ID: 34382483
[TBL] [Abstract][Full Text] [Related]
13. The effect of aromatase inhibitor on controlled ovarian stimulation for oocyte cryopreservation in adolescent and young cancer patients.
Suzuki R; Horage-Okutsu Y; Kawahara T; Nakamura K; Shiraishi E; Iwahata H; Suzuki-Takahashi Y; Sugishita Y; Takae S; Suzuki N
J Obstet Gynaecol Res; 2023 Mar; 49(3):973-979. PubMed ID: 36606606
[TBL] [Abstract][Full Text] [Related]
14. Back-to-back random-start ovarian stimulation prior to chemotherapy to maximize oocyte yield.
Wald K; Cakmak H; Mok-Lin E; Cedars M; Rosen M; Letourneau J
J Assist Reprod Genet; 2019 Jun; 36(6):1161-1168. PubMed ID: 31127475
[TBL] [Abstract][Full Text] [Related]
15. Ovarian response after random-start controlled ovarian stimulation to cryopreserve oocytes in cancer patients.
Campos APC; Geber GP; Hurtado R; Sampaio M; Geber S
JBRA Assist Reprod; 2018 Nov; 22(4):352-354. PubMed ID: 30264947
[TBL] [Abstract][Full Text] [Related]
16. Effects of cancer on ovarian response in controlled ovarian stimulation for fertility preservation.
Almog B; Azem F; Gordon D; Pauzner D; Amit A; Barkan G; Levin I
Fertil Steril; 2012 Oct; 98(4):957-60. PubMed ID: 22763097
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
[TBL] [Abstract][Full Text] [Related]
18. Ovarian stimulation for fertility preservation in women with cancer: A systematic review and meta-analysis comparing random and conventional starts.
Alexander VM; Martin CE; Schelble AP; Laufer AB; Hardi A; McKenzie LJ; Hipp HS; Kawwass JF; Spencer JB; Jungheim ES
J Gynecol Obstet Hum Reprod; 2021 Oct; 50(8):102080. PubMed ID: 33545413
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation.
Pereira N; Kelly AG; Stone LD; Witzke JD; Lekovich JP; Elias RT; Schattman GL; Rosenwaks Z
Fertil Steril; 2017 Sep; 108(3):532-538. PubMed ID: 28865552
[TBL] [Abstract][Full Text] [Related]
20. Antral follicle responsiveness to FSH, assessed by the follicular output rate (FORT), is altered in Hodgkin's lymphoma when compared with breast cancer candidates for fertility preservation.
Sonigo C; Comtet M; Duros S; Sifer C; Sermondade N; Grynberg M
J Assist Reprod Genet; 2018 Jan; 35(1):91-97. PubMed ID: 28986734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
